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Abstract
Background: To investigate disease progression the first 12 months after diagnosis in children with type 1
diabetes negative (AAB negative) for pancreatic autoantibodies [islet cell autoantibodies(ICA), glutamic acid
decarboxylase antibodies (GADA) and insulinoma-associated antigen-2 antibodies (IA-2A)]. Furthermore the study
aimed at determining whether mutations in KCNJ11, ABCC8, HNF1A, HNF4A or INS are common in AAB negative
diabetes.
Materials and methods: In 261 newly diagnosed children with type 1 diabetes, we measured residual b-cell
function, ICA, GADA, and IA-2A at 1, 6 and 12 months after diagnosis. The genes KCNJ11, ABCC8, HNF1A, HNF4A
and INS were sequenced in subjects AAB negative at diagnosis. We expressed recombinant K-ATP channels in
Xenopus oocytes to analyse the functional effects of an ABCC8 mutation.
Results: Twenty-four patients (9.1%) tested AAB negative after one month. Patients, who were AAB-negative
throughout the 12-month period, had higher residual b-cell function (P = 0.002), lower blood glucose (P = 0.004),
received less insulin (P = 0.05) and had lower HbA1c (P = 0.02) 12 months after diagnosis. One patient had a
heterozygous mutation leading to the substitution of arginine at residue 1530 of SUR1 (ABCC8) by cysteine.
Functional analyses of recombinant K-ATP channels showed that R1530C markedly reduced the sensitivity of the K-
ATP channel to inhibition by MgATP. Morover, the channel was highly sensitive to sulphonylureas. However, there
was no effect of sulfonylurea treatment after four weeks on 1.0-1.2 mg/kg/24 h glibenclamide.
Conclusion: GAD, IA-2A, and ICA negative children with new onset type 1 diabetes have slower disease
progression as assessed by residual beta-cell function and improved glycemic control 12 months after diagnosis.
One out of 24 had a mutation in ABCC8, suggesting that screening of ABCC8 should be considered in patients with
AAB negative type 1 diabetes.
Background
Type 1 diabetes (T1D) is thought to result from an
immune-mediated destruction of the pancreatic beta-
cells in genetically susceptible people. The risk for
developing T1 D seems to increase with genetic suscept-
ibility in combination with the presence of immunologi-
cal markers of beta-cell autoimmunity. Although the
destruction of the pancreatic beta-cell is perceived to be
mediated by T cells, the loss of immunological self-tol-
erance may result in autoantibody formation. Signs of
immunological activity directed against the pancreatic
beta-cell may appear many years before clinical disease
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Although not directly involved in beta-cell death, auto-
antibodies can be used as markers of beta-cell destruc-
tion and reflect disease severity. A subclass of T1 D
children does not show any of these signs of humoral
autoimmunity and are considered to have idiopathic or
Type 1 B diabetes. Children and adolescents with newly
diagnosed type 1 diabetes are more likely to present
with several autoantibodies than adults, probably reflect-
ing a stronger autoimmune state and a more severe dis-
ease progression.
Recently, there have been substantial improvements in
molecular genetic diagnostics of diabetes in infants. A
molecular diagnosis is now possible for glucokinase defi-
ciency (1), mutations in transcription factors HNF-1a
(2) or HNF-4 a (3), insulin gene mutations (4), and
mutations in the pancreatic ATP-sensitive potassium
(K-ATP) channel subunits KIR6.2 (5) and SUR1 (6, 7).
Since oral treatment with sulfonylurea has become an
attractive alternative for most of these patients, efforts
should be made to diagnose these defects in patients
with absence of autoantibodies against pancreatic anti-
gens (8, 9, 10).
The aims of the present study were: 1) to compare the
disease progression of type 1 diabetes among children
negative and children positive for ICA, GADA and IA-
2A, (subsequently referred to as autoantibody negative
and autoantibody positive) during the first 12 months
after disease onset, and 2) to investigate whether muta-
tions in the KCNJ11, ABCC8, HNF1A, HNF4A or INS
genes are common in children and adolescents with
AAB negative diabetes.
Methods
Subjects
This is a multicenter longitudinal investigation with 18
participating pediatric centers from 15 countries in Eur-
ope and Japan. A total of 261 children and adolescents
(132 girls, 129 boys, 84% Caucasian, 16% other ethnici-
t i e s )u pt o1 6y e a r so fa g ew e r ef o l l o w e df o r1 2m o n t h s
from the diagnosis of T1D: Clinical information on
demographics and anthropometry, insulin therapy as
well as blood samples for centralized measurement of
HbA1c and meal-stimulated C-peptide, proinsulin, and
GLP-1 were collected prospectively. Exclusion criteria
were: clinically suspected type 2 diabetes, diabetes in 3
consecutive generations with onset before age 25 (to
exclude maturity onset diabetes of the young (MODY)),
secondary diabetes, decline of enrolment into the study,
and patients initially treated outside the centers for
more than 5 days. Insulin regimens were recorded 1, 3,
6, 9 and 12 months after diagnosis. After 12 months,
52.9% of the children were on twice insulin daily. Only
three children used an insulin infusion pump while 13%
were treated with a rapid acting insulin analogue. Daily
insulin dose was 0.72 ± 0.28 IU/kg (mean ± SD).
The study was performed according to the criteria of
the Helsinki II Declaration and was approved by the
local ethical committee in each centre. All patients, their
parents or guardians gave written informed consent.
Glycemic control
Glycemic control as assessed by HbA1c was measured at
diagnosis, and at 1, 3, 6, 9 and 12 months after diagno-
sis. HbA1c was determined centrally by ion-exchange
high-performance liquid chromatography (reference
range 4.1-6.4%) at Steno Diabetes Center, Gentofte,
Denmark. We used insulin dose adjusted HbA1c
(IDAA1c) = HbA1c (%) + [4 × insulin dose (U/Kg/
24h)] as a marker of disease severity. This measure,
adjusting for the exogenous insulin, reflects the underly-
ing and theoretically untreated disease, as it mimics a
situation in which no insulin was administered. In this
setting it therefore reflects the severity of the disease
and hence is superior to the HbA1c alone (11).
Antibodies
As all patients were treated with insulin during the first
month after diagnosis, secondary insulin antibodies (IA)
could not be distinguished from primary insulin autoan-
tibodies (IAA) and, therefore, were not included in the
classification of the antibody pattern at 1 month.
Patients with detectable antibodies (IA-2A, GADA and/
or ICA) at 1 month were considered autoantibody-posi-
tive. Patients with an absence of autoantibodies (IA-2A,
GADA and/or ICA) at 1 month were considered auto-
antibody-negative.
ICA were detected by indirect immunofluorescence
using commercial Primate Pancreas slides from INOVA.
The sera were screened at a dilution of 1:2 and FITC-
labelled anti-human IgG (Dako, Copenhagen, Denmark)
was used as conjugate and grouped as negative 0-0.5 U.
GADA were quantified by a direct radioimmuassay
(Diamyd Diagnostics, Stockholm, Sweden). Sera were
run in duplicate, and the results were read on a gamma
counter (Wizard 1470; Wallac/PerkinElmer, Turku, Fin-
land) and calculated from a standard curve. The cut-off
limit was 10 U/ml, set from a comparison between 94
patients with type 1 diabetes and 98 healthy blood
donors. The intra- and interassay coefficients of varia-
tion were 2.9% and 5.1%, respectively (12).
IA-2A were analyzed with a radiobinding assay (13).
The results were expressed as relative units (RU) based
o nas t a n d a r dc u r v er u no ne a c hp l a t eu s i n ga na u t o -
mated calculation program (MultiCalc; Wallac). The
limit for IA-2A positivity (0.77 RU) was set at the 99th
percentile in 374 non-diabetic children and adolescents.
The inter-assay coefficient of variation was < 12%. IA
Pörksen et al. BMC Endocrine Disorders 2010, 10:16
http://www.biomedcentral.com/1472-6823/10/16
Page 2 of 10were measured by a modification of the method
described by Williams et al. (14), the cut-off limit for
positivity was 2.80 RU.
Residual beta-cell function
Mixed-meal stimulated serum C-peptide was used as a
marker of residual b-cell function after a disease dura-
tion of 1, 6, and 12 months. Serum samples were labeled
and frozen at - 20 °C until shipment on dry ice for the
determination of C-peptide within half a year.
Serum C-peptide was analyzed by a fluoroimmuno-
metric assay (AutoDELFIATM C-peptide, Perkin Elmer
Life and Analytical Sciences, Inc, Turku, Finland). The
analytical sensitivity was better than 5 pmol/l, the intra-
assay coefficient of variation was <6% at 20 pmol/l, and
recovery of standard, added to plasma before extraction,
about 100% when corrected for losses inherent in the
plasma extraction procedure. Total proinsulin-immunor-
eactivity was analyzed by a two-site ELISA based on the
monoclonal antibodies coating antibody PEP-001 and
detecting antibody HUI-001 (Novo Nordisk A/S, Bags-
værd, Denmark). The sensitivity was below 0.3 pmol/l.
Genotyping
Typing of the HLA-class II DRB1 locus was performed
by direct sequencing of exon 2 of DRB1 according to
the Immuno Histocompatibility Working Group. DR 03/
04 and DR 04/04 were defined as high-risk genotypes,
while DR 03/03 and DR 04/08 were considered to con-
vey moderate risk. All other genotypes were classified as
low-risk. The analysis of the variable number of tandem
repeats region of the insulin gene (INS-VNTR)w a sp e r -
formed as previously described by Nielsen et al. (15) We
sequenced coding exons and flanking intronic regions of
the genes HNF1A (16), HNF4A (17),I N S(18) and
KCNJ11 (5). All 39 exons, flanking intron and non-cod-
ing 5’ and 3’ untranslated regions of ABCC8 were
sequenced by a high-throughput, semi-automated strat-
egy as decribed by Sandal et al. (19).
Functional analysis
For functional analysis, we coexpressed wild-type or
mutant SUR1 together with wild-type Kir6.2 in Xenopus
laevis oocytes, as previously described (6). Whole-cell
currents were recorded using a 2-electrode voltage-
clamp in response to voltage steps of ± 20 mV from a
holding potential of -10 mV, in a solution containing (in
mM): 90 KCl, 1 MgCl2,1 . 8C a C l 2,5H E P E S( p H7 . 4
with KOH). Metabolic inhibition was induced by 3 mM
Na-azide, and 0.5 mM tolbutamide was used to block
KATP channels, as indicated. Data were analysed with
pCLAMP8 (Axon Instruments, CA, USA), Origin 6.02
(Microcal Software, Northampton, MA, USA) and Igor
(Wavemetrics, Lake Oswego, OR, USA) software and
are given as mean+SEM. Statistical significance was
evaluated using an unpaired two-tailed Student’st - t e s t .
A probability value of P < 0.05 was considered a signifi-
cant difference.
Statistical methods
C-peptide, and proinsulin were investigated by means of
the logarithmic scale. C-peptide, proinsulin, blood glu-
cose change, insulin dose, HbA1c and IDAA1c were ana-
lysed by multiple regression with age, sex, and antibody
status (negative/positive) as explanatory variables in a
compound symmetric repeated measurement model. A
P-value < 0.05 was considered significant. Statistical ana-
lyses were performed using SAS version 9.1 (SAS Insti-
tute, USA, Inc, Cary, NC, USA).
Results
Twenty-four patients (9.1%, Table 1 and 2) out of 261
tested negative for GADA, IA-2A, and ICA after 1
month. Of these, 22 were also negative at 6 and 12
months after diagnosis, whereas one of the patients ser-
oconverted to positivity at six months (IA-2A) and
another at 12 months (GADA). The group of 22
patients remaining autoantibody-negative (Table1) did
not differ significantly from the autoantibody-positive
group with respect to sex (P = 0.40), age (P = 0.49), eth-
nicity (P = 0.80,), HLA risk groups (p = 0.68) or INS-
VNTR genotypes. Autoantibody-negative patients had
lower titers of Insulin Antibodies at 1 month after diag-
nosis (P = 0.01), not shown. Six of 22 (27%) autoanti-
body-negative patients had first-degree relatives with
diabetes compared with 22 of 237 autoantibody-positive
subjects (10%) (P = 0.01) indicating that genetic factors
may be of predominant importance. None of the 6 auto-
antibody-negative patients with a family history of dia-
betes had mutations in HNF1A or HNF4A. There were
no INS gene mutations in the autoantibody negative
group.
Better residual beta-cell function and glycemic control in
autoantibody-negative subjects
The residual beta-cell function (as assessed by meal-
stimulated C-peptide) in the 22 persistently
autoantibody-negative patients was twice as high as in
autoantibody-positive patients 12 months after diagnosis
(P = 0.005, Fig. 1A), and the proinsulin values were cor-
respondingly higher in autoantibody-negative patients
(P = 0.01, Fig. 1B). Moreover, the autoantibody-negative
patients experienced lower blood glucose changes
( 2 . 4m m o l / L )d u r i n gt h eB o o s tt e s ta t1 2m o n t h so f
follow-up (P = 0.004, Fig. 1C). During the 12 months
follow-up glycemic control was significantly better in
autoantibody-negative patients as they had 0.65% (abso-
lute) lower HbA1c than autoantibody-positive subjects
Pörksen et al. BMC Endocrine Disorders 2010, 10:16
http://www.biomedcentral.com/1472-6823/10/16
Page 3 of 10Table 1 Clinical characteristics of the 22 study participants who remained negative for autoantibodies: GADA, IA-2A, and ICA 1, 6, and 12 months after
diagnosis of type 1 diabetes
Patient Age Sex BMI
(kg/m
2)
HbA1C
0 (%)
IDAA1C
1
IDAA1C
6
IDAA1C
12
Ins dose1
(U/kg/day)
ins dose6
(U/kg/day)
Ins dose12
(U/kg/day)
Cpep1
(pmol/L)
Cpep6
(pmol/L)
Cpep12
(pmol/L)
BGstim1
(mmol/L)
BGstim6
(mmol/L)
BGstim12
(mmol/L)
1 16.3 female 31.14 11.8 Na 7.1 6.8 0.33 0.22 0.33 1055 201 272 14.33 10 9.1
3 6.6 female 14.31 6.3 Na Na 7.3 Na Na 0.22 416 79 208 8.7 7.5 10.6
4 14.2 female 14.9 12.8 11.5 8.5 10 0.24 0.22 0.51 902 617 735 8.9 11.4 15.9
6 6.7 male 12.8 9.1 10.2 8.1 8.7 0.33 0.3 0.46 392 413 277 13.7 14.5 11.4
7 1.4 male 13.7 11.1 10.3 8.2 10.6 0.25 0.23 0.5 184 67 21 13.2 13.4 15.6
9 7 male 14.26 9 9.2 9.4 11.7 0.33 0.38 0.74 18 21 13 8.9 10.2 8.4
10 10.8 female 17.6 10.4 10.6 8.4 8.6 0.63 0.49 0.56 592 472 320 11.1 19.9 20.7
11 14.2 female 15.1 14.2 15.6 10.9 10.8 1.10 0.77 0.71 411 347 291 15.6 18.7 20.7
12 4.7 female 15.7 9.3 11.1 8.2 9.4 0.71 0.52 0.6 238 299 212 7.8 11.7 18.3
14 14.1 male 31.6 12 10.1 6.4 6.5 0.18 0.1 0.1 1353 1517 1147 6.2 5.8 5.0
15 3.6 male 11.5 15.3 13.2 9.8 13.7 0.44 0.39 0.84 479 380 216 10.1 Na Na
16 11.2 male 16.4 10.9 11.7 7.1 8.0 0.63 0.2 0.41 577 294 590 10.3 7.2 9.2
17 3 female 17.72 8.3 8.6 7.4 7.1 0.39 0.3 0.57 379 252 2721 8.7 5.7 11.4
18 6.3 female 17.2 9.3 9.5 Na 7.8 0.48 0.41 0.38 417 886 495 9.4 12.3 11.7
19 11.3 female 14.4 13.2 12.5 10.8 11.1 0.70 0.94 0.89 514 376 437 14.7 10.7 12.7
20 14 male 19.4 13 12.5 7.4 11.3 0.52 0.37 0.44 374 272 615 10.3 8.9 16.3
21 3.1 male 14.4 11 9.9 9.0 Na 0.25 0.45 0.75 91 101 183 12.5 17.7 19.2
22 3.1 male 14.4 8.6 9.3 9.8 11.0 0.35 0.41 0.64 309 229 176 15.0 18.0 19.9
23 10.5 male 17.3 14.3 Na 11.7 13.0 0.91 1.0 1.4 312 210 156 10.4 14.4 15.7
25 11.1 female Na 13 11.3 11.7 13.0 0.90 1.0 1.44 292 628 450 7.1 11.1 12.9
26 11.1 female 27.4 10.2 10.9 7.3 7.6 0.52 0.57 0.5 2040 1226 701 6.9 6.3 4.1
27 8.8 female Na 9 9.4 8.5 10.1 0.30 0.31 0.69 596 482 318 9.4 23.6 20.3
Mean 8.4 16.9 11.0 10.9 8.9 9.9 0.49 0.47 0.64 518.4 436.6 489.6 10.4 12.5 14.0
SD 4.2 4.9 2.4 1.7 1.6 2.1 0.24 0.27 0.32 448.6 375.8 577.5 2.7 5.1 5.1
Abbreviations: SD, standard deviation; Na, not available; BMI, body mass index; HBA1C0, HBA1C at diagnosis; IDAA1C 1, Insulin Dose Adjusted HbA1c (IDAA1C) at 1 month; IDAA1C 6, IDAA1C at 6 months; IDAA1C 12,
IDAA1C at 12 months; Ins dose1, insulin dose at 1 month; Ins dose6, insulin dose at 6 months; Ins dose12, insulin dose at 12 months; Cpep1, stimulated C-peptide at 1 month, Cpep6, stimulated C-peptide at 6
months; Cpep12, stimulated C-peptide at 12 months; BGstim1, 90 min glucose at 1 month; BGstim6, 90 min glucose at 6 months; BGstim12, 90 min glucose at 12 months.
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0(P = 0.04, data not shown). In terms of insulin require-
ment, the autoantibody-negative patients received 0.15
IU/kg/day less insulin 12 months after diagnosis com-
pared with autoantibody-positive subjects (P =0 . 0 2 )
(Fig. 1D). Twelve months after diagnosis, autoantibody-
negative children had on an average 1.25% (absolute)
lower insulin dose adjusted HbA1c (IDAA1c) than
autoantibody-positive children (P = 0.005) (Fig. 1E).
Mutation in ABCC8
We screened both the KCNJ11 and ABCC8 genes in all
24 subjects negative for autoantibodies (IA-2A, GADA
and/or ICA) at one month after diagnosis. None had a
mutation in KCNJ11. However, we identified a novel
heterozygous mutation in ABCC8:aC>Tc h a n g e
leading to a predicted Arg > Cys substitution at codon
1530 of SUR1 (Table 2) in one subject. This amino
acid residue is conserved from zebrafish to humans and
is located in the second nucleotide-binding domain of
SUR1, a region previously implicated in neonatal
diabetes.
We studied the functional effects of the SUR1-
R1530C mutation by expressing recombinant KATP
channels in Xenopus oocytes. Wild-type KATP channels
are normally closed when expressed in Xenopus oocytes
due to the high intracellular ATP concentration, but
they are activated by metabolic inhibitors such as azide,
which lower ATP (Fig. 2). In contrast, in oocytes
expressing SUR1-R1530C mutant channels significant
resting whole-cell KATP currents were present in the
absence of metabolic inhibition (Fig. 2). Thus, basal cel-
lular metabolism causes less block of mutant KATP
channels than wild-type channels. Mutant channel cur-
rents were increased by 3 mmol/l azide, indicating that
they can be further activated by metabolic inhibition.
Importantly, mutant channels were blocked by 0.5
mmol/l tolbutamide (Fig. 3), a concentration that fully
saturates the high-affinity-binding site for sulfonylureas.
There was no difference in the potency of block for
wild-type and mutant channels: 91 ± 3% (n = 4) v 84 ±
7% (n = 4) respectively (Fig. 3).
The patient and first-degree relatives
The patient with the ABCC8 mutation was 13 years old
when diagnosed (Table 2). He had a high risk HLA
profile (DR 04/04) and became positive for IA-2A 6
months after diagnosis. He had no first-degree relatives
with diabetes. The mother was negative for the muta-
tion in the ABCC8 gene and the father was unavailable
for mutation analysis. Although functional analyses
showed that the mutant channel was highly sensitive to
sulfonylureas, there was no clinical effect on metabolic
control or insulin requirement after four weeks of glib-
enclamide treatment (1.0-1.2 mg/kg/24h) 8 years after
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Figure 1 Comparison of disease course in autoantibody-negative and autoantibody-positive children: A: 12 months after disease onset,
the residual beta cell function in autoantibody-negative patients was twofold higher than in autoantibody-positive patients (p = 0.002). B:
Autoantibody-negative patients had significantly higher proinsulin release 12 months after disease diagnosis than autoantibody-positive subjects
(P = 0.01). C: The blood glucose change (90 minutes value minus fasting value) during meal-stimulation differed significantly between
autoantibody-negative and autoantibody-positive patients 12 months after disease onset (P = 0.004). D: 12 months after diagnosis autoantibody-
negative patients received about 0.15 IU/kg/day less insulin than autoantibody-positive subjects (P = 0.02). E: Autoantibody-negative subjects had
0.8% lower IDAA1c than autoantibody-positive patients (P = 0.02).
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Page 6 of 10diagnosis of diabetes. We believe that the patient devel-
oped T1 D in addition to the ABCC8-diabetes as he
now is insulin-dependent, C-peptide- and IA-2A-nega-
tive but GADA-positive (14.9 U/ml, cut-off limit is 10
U/ml) and therefore had no beneficial effects of sulpho-
nylurea treatment. Meal-stimulated GLP-1 and GIP did
not differ between the subject carrying the R1530C
mutation and non-carriers (data not shown).
Discussion
This study shows that 9,1% of children and adolescents
with newly diagnosed type 1 diabetes did not have auto-
antibodies for ICA, GADA and IA-2A on initial testing
or on 12 months follow-up (Table 1). This is consistent
with a recent study on children and adolescents by
Rubio-Cabezas where 9,9% tested negative for the same
pancreatic autoantibodies(20)
We find that, when investigated in a physiologic set-
ting, residual beta-cell function was considerably
improved in autoantibody-negative (GADA, ICA, IA-
2A) children with T1 D compared with autoantibody-
positive (GADA, ICA, IA-2A) T1 D one year after diag-
nosis (Fig. 1A,B). The patients also had better glycemic
control and required less exogenous insulin underscor-
ing the milder disease process in patients with autoanti-
body-negative T1 D (Fig. 1C,D,E). We measured
autoantibodies at 1, 6, and 12 months after diagnosis,
and since we had no measurement at diagnosis, theore-
tically we cannot rule out the possibility that some
patients might have been autoantibody positive at
diagnosis and during the first month experienced sero-
conversion to antibody-negativity. On the other hand,
none of the 239 subjects who were autoantibody-posi-
tive at one month converted to autoantibody-negative
within the 12 months after diagnosis. We decided to
exclude IA from our definition of autoantibody negativ-
ity, because we did not measure autoantibodies at onset.
We do not think this biased our study, as at disease pre-
sentation very few patients are positive for insulin auto-
antibodies only (21). However, in the present study
autoantibody-negative patients also had lower titers of
IA at 1 month after diagnosis, further underscoring a
lower immunological response and milder disease pro-
gression in this group of patients.
Recently it has been established that presence of auto-
antibodies directed against the beta cell zinc transporter
ZnT8 are associated with type 1 diabetes. We have not
included ZnT8 antibodies in our study but in a recent
study in adults 1.4% of the GADA and IA-2A negative
patients were ZNT8 positive (22). Therefore in future
studies the inclusion of ZnT8 AB is mandatory to differ-
entiate clinical phenotypes.
In our study we did not find any association with anti-
body (ICA, GADA, IA-2A) status and HLA risk alleles.
It is possible that this could be explained by the absence
of ZnT8 antibody status in the present study, and that
inclusion of these might have revealed such an
association.
Our findings indicate that a positive family history of
diabetes may play a role, not related to the classical T1
Dl o c i( H L Aa n dINS-VNTR).A ni m p o r t a n tq u e s t i o ni s
whether the 22 patients who remained autoantibody-
negative truly had T1 D. At study entry the diagnosis of
wt
R1531C
azide
Tolbutamide
0.5 µA
0.5 µA
Figure 2 Tolbutamide response in SUR1-R1530C.W h o l e - c e l l
currents recorded from Xenopus oocytes coexpressing Kir6.2 and
either SUR1 (WT) or SUR1-R1530C in response to voltage steps of
+20 mV from a holding potential of -10 mV. Bars indicate the times
of application of 3 mmol/l azide or 0.5 mmol/l tolbutamide.
Figure 3 Tolbutamide response in SUR1-R1530C.M e a ns t e a d y -
state whole-cell K-ATP currents (as indicated) evoked by a voltage
step from -10 to -30 mV before (rest; grey bars) and after
application of 3 mmol/l azide (grey bars) and in the presence of 3
mmol/l azide plus 0.5 mmol/l tolbutamide (black bars). Four oocytes
were used for each experiment. *P < 0.05against control (t-test).
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recommendations, and the responsible clinician at each
center established the diagnosis of T1 D by her/his clini-
cal judgment. Patients with suspected type 2 diabetes
and patients with a family history of diabetes in three
consecutive generations and with onset before the age
of 25 years (suspected monogenic diabetes) were
excluded. In the 6 antibody-negative patients with a
positive family history, we did not find any mutations in
HNF1A or HNF4A. We did not screen patients without
a family history of diabetes for mutations and do not
think we overlooked monogenic diabetes in these
patients as spontaneous mutations are rare, although
not impossible, in the transcription factor MODY genes
(15, 17, 23, 24). On the other hand, neonatal diabetes
due to mutations in INS (4, 17, 25) or either of the
genes encoding the K-ATP subunits KIR6.2 (5) and
SUR1 (6, 7) occurs de novo in approximately 50% of the
cases and these subjects typically present with autoanti-
body-negative insulin-dependent diabetes. Relevant for
the present study is our recent observation that INS
mutations can be a cause of antibody-negative diabetes
presenting as T1 D (18). Thus, we regarded INS,
KCNJ11 and ABCC8 being good candidate genes in our
antibody-negative patients.
We did not find pathogenic mutations in INS or
KCNJ11, but one subject had a heterozygous mutation
(R1530C) in SUR1 encoded by ABCC8. We believe this
mutation is pathogenic because: (1) arginine at codon
1530 is conserved through evolution from zebrafish to
humans; (2) codon 1530 is located in the second nucleo-
tide-binding domain of SUR1, and other mutations in
this domain cause permanent and transient neonatal
diabetes and (3) functional analysis showed that homo-
zygous mutant channels were ~three-fold more active at
rest than wild-type channels. This suggests that the K-
ATP current magnitude will also be increased in the
beta-cell and in the heterozygous state, and can explain
the diabetes of the patient.
Although our functional analyses showed that the
channel was highly sensitive to sulphonylureas, our
patient (8 years after diagnosis of diabetes) did not ben-
efit from glibenclamide after 4 weeks of treatment (1.0-
1.2 mg/kg/24h) in terms of metabolic control and insu-
lin requirement. The 13-year-old male patient serocon-
verted to IA-2A positivity 6 months after diagnosis. It
has been shown that adult-onset diabetes caused by
SUR1 mutations responds favorably to sulphonylurea
treatment (26). A possible explanation for the unsuc-
cessful sulphonylurea treatment in our patient, despite
promising functional studies of the K-ATP-channel,
might be that the patient developed autoimmune dia-
betes. He had a high risk HLA profile, which might also
facilitate the progression to autoimmune diabetes.
Conclusions
In conclusion GADA, IA-2A, and ICA-negative children
with T1 D have slower disease progression including
better preservation of b-cell function and improved gly-
caemic control 12 months after diagnosis. A mutation
within the ABCC8 g e n em a yb ea ,s of a r ,u n i d e n t i f i e d
cause of autoantibody-negative childhood-onset diabetes,
also after the neonatal period.
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